Valproate: Not All Boxed Warnings Are Created Equal

CONCLUSIONS: Overstated monitoring recommendations for the potential risk of hepatotoxicity and pancreatitis distracts from a much more common and severe risk of fetal harm. Clinicians must be diligent about discussing this risk with patients and documenting when this discussion occurs. Changes to the current recommendations for monitoring of the boxed warnings associated with valproate therapy should be considered, such as more stringent monitoring requirements for the inherent fetal risk. This could be accomplished through a Risk Evaluation and Mitigation Strategy program or through institution-based policies and procedures. In addition, monitoring recommendations for the risk of hepatotoxicity and pancreatitis should account for contributing risk factors.PMID:35392666 | DOI:10.1177/10600280221085991
Source: The Annals of Pharmacotherapy - Category: Drugs & Pharmacology Authors: Source Type: research